RxDoctor Payments Data

Rachael Compeau, NP

Family · Flint, MINPI 1427587120

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (33.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 45 manufacturers reported payments, led by Teleflex LLC at 56.1% of the total. Among family clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$62,190in general payments, 2019–2025

Across 751 payments — averaging $82.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$35K
  • Axonics, Inc.$18K
  • Astellas Pharma US Inc$1K
  • Sumitomo Pharma America, Inc.$1K
  • Johnson & Johnson$789
  • AbbVie$651
  • plus $6K from 39 others

What the payments were for

  • Consulting fees$7,13911%
  • Speaking & faculty fees$20,98934%
  • Travel & lodging$14,99024%
  • Food & beverage$18,41530%
  • Education$6581%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,190 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$26,785
Medicare patients
154
Services billed
596

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron149$123,842
GemtesaVibegron76$85,593
Mirabegron ErMirabegron59$44,706
PremarinEstrogens, Conjugated12$5,115
Methenamine Hippurate56$2,885
Tolterodine Tartrate ErTolterodine Tartrate22$2,743
Tamsulosin Hcl104$1,853
Oxybutynin Chloride ErOxybutynin Chloride62$1,238
Estradiol12$1,056
NitrofurantoinNitrofurantoin Macrocrystal25$914
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst90$898
Alfuzosin Hcl ErAlfuzosin Hcl27$484
Cefdinir12$376
Cephalexin47$279
Finasteride14$247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,101$123,842149 claims
Sumitomo Pharma America, Inc.Gemtesa$1,032$85,59376 claims
PfizerPremarin$563$5,11512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.

Other family in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →